Evaluation of breast cancer using proton MR spectroscopy: Total choline peak integral and signal-to-noise ratio as prognostic indicators

American Journal of Roentgenology

Volumn 198, Issue 5, 2012, Pages

  Shin, Hee Jung ^a   Baek, Hyeon Man ^b   Cha, Joo Hee ^a   Kim, Hak Hee ^a  

^a University of Ulsan   (South Korea)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Breast; Breast neoplasm; MR spectroscopy; Prognostic factor

Indexed keywords

CHOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CONTROLLED STUDY; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL NOISE RATIO; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CHOLINE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SIGNAL-TO-NOISE RATIO; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84860318261     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7292     Document Type: Article

References (35)

1. Bedrosian I, Mick R, Orel SG, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003; 98:468-473 (Pubitemid 36885985)
2. Warner E, Plewes DB, Shumak RS, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001; 19:3524-3531 (Pubitemid 32730090)
3. Nunes LW, Schnall MD, Orel SG, et al. Breast MR imaging: interpretation model. Radiology 1997; 202:833-841 (Pubitemid 27093463)
4. den Boer JA, Hoenderop RK, Smink J, et al. Pharmacokinetic analysis of Gd-DTPA enhancement in dynamic three-dimensional MRI of breast lesions. J Magn Reson Imaging 1997; 7:702-715
5. Kuhl CK, Mielcareck P, Klaschik S, et al. Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 1999; 211:101-110 (Pubitemid 29161739)
6. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5:303-324
7. Cheng LL, Chang IW, Smith BL, Gonzalez RG. Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J Magn Reson 1998; 135:194-202 (Pubitemid 128450704)
8. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998; 209: 269-275 (Pubitemid 28464677)
9. Gribbestad IS, Singstad TE, Nilsen G, et al. In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging 1998; 8:1191-1197 (Pubitemid 28533659)
10. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 2001; 68:45-54 (Pubitemid 32928270)
11. Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy - initial results. Radiology 2001; 220:40-46 (Pubitemid 32577957)
12. Tse GM, Cheung HS, Pang LM, et al. Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. AJR 2003; 181: 1267-1272 (Pubitemid 37296401)
13. Bolan PJ, Meisamy S, Baker EH, et al. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003; 50:1134-1143 (Pubitemid 37494015)
14. Bartella L, Morris EA, Dershaw DD, et al. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 2006; 239:686-692 (Pubitemid 43830603)
15. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999; 59:80-84 (Pubitemid 29062961)
16. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm 2006; 3:496-506 (Pubitemid 44639126)
17. Yeung DK, Yang WT, Tse GM. Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases. Radiology 2002; 225:190-197
18. Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy - a pilot study at 4 T. Radiology 2004; 233:424-431 (Pubitemid 39423801)
19. Kumar M, Jagannathan NR, Seenu V, Dwivedi SN, Julka PK, Rath GK. Monitoring the therapeutic response of locally advanced breast cancer patients: sequential in vivo proton MR spectroscopy study. J Magn Reson Imaging 2006; 24:325-332 (Pubitemid 44188558)
20. Lean C, Doran S, Somorjai RL, et al. Determination of grade and receptor status from the primary breast lesion by magnetic resonance spectroscopy. Technol Cancer Res Treat 2004; 3:551-556 (Pubitemid 40023544)
21. Shapiro C, Barsky SH. Infiltrating carcinomas of the breast: not one disease. In: Bland KI and Copeland EM. The breast, 4th ed. Philadelphia, PA: Saunders Elsevier, 2009:231-247
22. Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA 2001; 12:141-152 (Pubitemid 32510133)
23. Pijnappel WWF, Vandenboogaart A, de Beer R, van Ormondt D. Svd-based quantification of magnetic resonance signals. J Magn Reson 1992; 97:122-134
24. Ratiney H, Sdika M, Coenradie Y, Cavassila S, van Ormondt D, Graveron-Demilly D. Time-domain semi-parametric estimation based on a metabolite basis set. NMR Biomed 2005; 18:1-13 (Pubitemid 40347537)
25. Knijn A, de Beer R, van Ormondt D. Frequency-selective quantification in the time domain. J Magn Reson 1992; 97:444-450
26. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403-410
27. Baek HM, Chen JH, Nalcioglu O, Su MY. Diagnostic value of breast proton magnetic resonance spectroscopy at 1.5 T in different histological types. Proc Intl Soc Mag Reson Med 2009; 17:587
28. Ramírez de Molina A, Gutiérrez R, Ramos MA, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002; 21:4317-4322 (Pubitemid 34753838)
29. Chen JH, Baek HM, Nalcioglu O, Su MY. Estrogen receptor and breast MR imaging features: a correlation study. J Magn Reson Imaging 2008; 27:825-833 (Pubitemid 351508098)
30. Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353:1652-1654 (Pubitemid 41464703)
31. Stefano R, Agostara B, Calabro M, et al. Expression levels and clinical-pathological correlations of HER2/neu in primary and metastatic human breast cancer. Ann N Y Acad Sci 2004; 1028:463-472 (Pubitemid 40361848)
32. Baek HM, Chen JH, Nalcioglu O, Su MY. Choline as a biomarker for cell proliferation: do the results from proton MR spectroscopy show difference between HER2/neu positive and negative breast cancers? Int J Cancer 2008; 123:1219-1221
33. Agrawal G, Chen JH, Baek HM, et al. MRI features of breast cancer: a correlation study with HER-2 receptor. Ann Oncol 2007; 18:1903-1904 (Pubitemid 350111577)
34. Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 2000; 191:1-6
35. Sardanelli F, Fausto A, Di Leo G, de Nijs R, Vorbuchner M, Podo F. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. AJR 2009; 192:1608-1617